Pulmonology

The geko device is designed to increase blood circulation and edema reduction to prevent venous thrombosis in non-surgical patients.

The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.

The indication makes it the first respiratory biologic available either at home or in a professional setting, with eight-week maintenance dosing.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.

Outside of CPAP, what therapies—invasive and non-invasive—exist for patients?

A new study shows that approximately one-quarter of adults aged 18-34 years old with a medical condition have used marijuna in the past month.

Albert Rizzo, MD, the chief medical officer of the American Language Association, answers questions about and discusses the dangers of vaping and e-cigarette use in the latest edition of the DocTalk Podcast.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

The Allergenic Products Advisory Committee voted in favor Friday to support the BLA data for what could become the first drug indicated for food allergy desensitization.

A recent analysis that included data on 284 patients found that more than 80% of patients with resistant hypertension also had obstructive sleep apnea.

The biologic becomes the first in its drug class to be indicated for patients aged 6-11 years old with the difficult-to-treat condition.

Obstructive sleep apnea has been consistently underdiagnosed in US populations. Are screening methods enough?

Addressing the drivers of poor sleep conditions is among the many ways a physician can treat patients without prescription.

How a pattern of poor sleep could begin a cycle of worsened respiratory and cardiovascular health.